Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).

Ikuko HiraiKeiji TaneseYoshio NakamuraKeitaro FukudaTakeshi OuchiTetsu HayashidaKaori KameyamaTakayuki AbeMasayuki AmagaiTakeru Funakoshi

Published in: The oncologist (2024)

The combination of docetaxel and trastuzumab demonstrated a favorable clinical effect and acceptable tolerability, which makes it a good treatment option for HER2-positive metastatic EMPD (ClinicalTrials.gov Identifier: UMIN000021311, jRCTs031180073).

Keyphrases

phase ii
clinical trial
open label
double blind
epidermal growth factor receptor
placebo controlled
phase iii
squamous cell carcinoma
small cell lung cancer
study protocol
metastatic breast cancer
locally advanced
randomized controlled trial
radiation therapy
combination therapy
tyrosine kinase
replacement therapy